v3.26.1
Collaborative and Other Relationships - Lily (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 199 Months Ended
Dec. 31, 2009
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
License Agreements            
Total revenues   $ 1,674,039 $ 1,215,529 $ 2,946,715 $ 2,268,427  
Eli Lilly            
License Agreements            
Upfront payment received under license agreement           $ 100,000
Eli Lilly | OLUMIANT            
License Agreements            
Total revenues   $ 38,500 $ 33,500 $ 74,900 $ 64,300  
Development Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           149,000
Development Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement $ 150,000          
Regulatory Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           335,000
Regulatory Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement 365,000          
Commercialization Milestones | Eli Lilly            
License Agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 50,000
Commercialization Milestones | Maximum | Eli Lilly            
License Agreements            
Upfront and immediate milestone payment to be received under license agreement $ 150,000